New Delhi: The Ministry of External Affairs (MEA) said "selective" reporting has been done referring to reports on communication from the MEA asking pharma company Bharat Biotech to address issues to avoid cancellation of WHO's emergency use approval (EUA) for its Covid-19 vaccine.
"Selective parts of the communication have been highlighted out of context to portray an incorrect picture," MEA sources told news agency ANI.
Sources told ANI that there have been media reports apparently quoting a communication from the MEA to Dr VK Paul, a member of NITI Aayog.
"It appears that this refers to an internal document circulated to members of the Empowered Group-5, which comprehensively looks at all issues related to vaccines," sources told news agency ANI on Friday.
READ | Can't Function On A Day's Backup: Delhi Govt Minister Satyendar Jain On Power Supply Crisis
In the note, there are several issues in a factual manner and does not indicate MEA's position or comment on any issue under consideration.
The World Health Organization (WHO) earlier said that it suspended the supply of Covaxin through United Nations agencies in response to the need to conduct process and facility upgrades to address recently identified GMP (good manufacturing practice) deficiencies.
The UN body, although, has clarified that there are no issues related to the safety and efficacy of the vaccine. The MEA has further said that people who have taken this Covid vaccine will not face any issues while travelling internationally as well.